Loading...
•
Dec 31, 2019
Atara Q4 2019 Earnings Report
Atara reported financial results and business highlights for Q4 2019.
Key Takeaways
Atara Biotherapeutics reported a net loss of $78.5 million for the fourth quarter of 2019. The company's cash, cash equivalents, and short-term investments totaled $259.1 million as of December 31, 2019, which, combined with proceeds from the ATM facility, are expected to fund operations into the second quarter of 2021.
Advanced tab-cel Phase 3 development for EBV+ PTLD.
Submitted clinical trial applications to several European countries to enable opening of EU clinical sites in 2020.
Continued Phase 1a clinical study of ATA188 in patients with progressive MS.
Progressed preclinical IND-enabling studies for ATA3219 and ATA3271 CAR T programs.
Atara
Atara
Forward Guidance
Atara believes that its cash, cash equivalents and short-term investments as of December 31, 2019, together with the net proceeds from the “at-the-market” (ATM) facility in January 2020, are sufficient to fund planned operations into the second quarter of 2021
Positive Outlook
- Initiate a tab-cel® biologics license application (BLA) submission for patients with EBV+ PTLD in the second half of 2020
- Discuss the totality of tab-cel® results with the U.S. Food and Drug Administration (FDA) in a pre-BLA meeting prior to initiating the BLA submission
- Submit a tab-cel® EU marketing authorization application for patients with EBV+ PTLD in 2021
- Initiate enrollment in a tab-cel® Phase 2 multi-cohort study including up to six additional ultra-rare EBV+ diseases in the second half of 2020 based on previous clinical data treating these patients
- Initiate enrollment of a randomized, double-blind, placebo-controlled Phase 1b study in patients with progressive MS in the second or third quarter of 2020